Irrational use of azithromycin in typhoid endemic areas: A challenge on multidrug-resistant typhoid treatment

Irfan Ullah, Kiran Shafiq Khan, Qasim Mehmood, Muhammad Junaid Tahir, Muhammad Irfan Malik, Ali Ahmed, Muhammad Usman Munir

Abstract


Typhoid is a food-borne fatal disease caused by Salmonella typhi. It causes inflammation of the intestine, resulting in diarrhoea, fever, headache, cough, and muscle pain. Improved hygiene has resulted in a marked decline in typhoid fever cases in many developed countries. However, significant typhoid cases emerge in low and middle-income countries annually, including Pakistan. Typhoid fever accounts for a larger percentage of acute febrile illnesses in Pakistan. Azithromycin is the only effective drug used in multidrug-resistant typhoid. The emergence of drug resistance typhoid has been of more significant concern in recent years due to its irrational use of azithromycin. It is considered the last antibiotic to eradicate multidrug-resistant typhoid fever from Pakistan. In this article, we express our concern of the irrational use of azithromycin in Pakistan and its effect on typhoid in the country.


Full Text:

PDF

References


Andrews JR, et al. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. The Lancet Infectious Diseases 2019; 19(1):e26-e30.

Aziz S and Malik L. Emergence of multi-resistant enteric infection in a Paediatric unit of Karachi, Pakistan. J Pak Med Assoc 2018; 68(12):1848-1850.

Berger D, et al. Paediatric Salmonellosis—Differences between Tropical and Sub-Tropical Regions of Queensland, Australia. Tropical medicine and infectious disease 2019; 4(2):61.

Browne AJ, et al. Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis. BMC medicine 2020; 18(1):1-22.

Doan T, et al. Open forum infectious diseases, Mass azithromycin distribution and community microbiome: a cluster-randomized trial. 2018.

Mboya EA, et al. Irrational use of antibiotics in the Moshi Municipality Northern Tanzania: a cross sectional study. Pan African Medical Journal 2018; 31(1).

Mogasale V, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. The Lancet Global health 2014; 2(10):e570-e580.

Mohan VK, et al. Safety and immunogenicity of a Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clinical Infectious Diseases 2015; 61(3):393-402.

Naveed A and Ahmed Z. Treatment of typhoid fever in children: comparison of efficacy of ciprofloxacin with ceftriaxone. European Scientific Journal 2016; 12(6).

NIH. Weekly Field Epidemiology Report 2019. 2019. https://www.nih.org.pk/wp-content/uploads/2019/06/FELTP-Pakistan-Weekly-Epidemiological-Report-June-10-16-2019.pdf. (Accessed: 2020, 29 August).

NIH. Weekly Field Epidemiology Report (36) 2020. 2020. https://www.nih.org.pk/wp-content/uploads/2020/09/36-FELTP-Pakistan-Weekly-Epidemiological-Report-Aug-30-Sep-05-2020.pdf. (Accessed: 2020, 30 September).

Organization WH. 2020. Pakistan first country to introduce new typhoid vaccine into routine immunization programme. 2019.

Qamar FN, et al. Strategies to improve coverage of typhoid conjugate vaccine (TCV) immunization campaign in Karachi, Pakistan. Vaccines 2020; 8(4):697.

Tita AT, et al. Adjunctive azithromycin prophylaxis for cesarean delivery. Obstetric anesthesia digest 2017; 37(2):59-60.

Vashishtha VM and Kalra A. The need & the issues related to new-generation typhoid conjugate vaccines in India. The Indian journal of medical research 2020; 151(1):22.




DOI: https://doi.org/10.24815/tigh.v1i2.23580

Refbacks

  • There are currently no refbacks.



2021 | Trends in Infection and Global Health (TIGH)